BeiGene is a commercial-stage biopharmaceutical company rooted in China that is dedicated to becoming a global leader in the discovery, development and commercialization of innovative, molecularly targeted and immuno-oncology drugs for the treatment of cancer.
We have three internally-developed late-stage clinical drug candidates:
- Zanubrutinib (BGB-3111) — an investig...
|Stock Quote||more >|
02/16/18 4:00 p.m. ET
Currency is USD
Data provided by Nasdaq. Minimum 15 minutes delayed.
|Recent Press Releases||more >|
|BeiGene Presents Preliminary Phase 1 Data on Tislelizumab in Patients with Urothelial Carcinoma at 2018 Genitourinary Cancers Symposium - February 9, 2018|
|CAMBRIDGE, Mass., and BEIJING, China, Feb. 09, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stag... Read More|
|BeiGene to Present at the LEERINK Partners 7th Annual Global Healthcare Conference - February 7, 2018|
|CAMBRIDGE, Mass. and BEIJING, China, Feb. 07, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage... Read More|